- Home
- HQH vs AKBA Comparison
HQH vs AKBA Comparison
Compare HQH & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQH
- AKBA
- Stock Information
- Founded
- HQH 1986
- AKBA 2007
- Country
- HQH United States
- AKBA United States
- Employees
- HQH N/A
- AKBA N/A
- Industry
- HQH Finance Companies
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- HQH Finance
- AKBA Health Care
- Exchange
- HQH Nasdaq
- AKBA Nasdaq
- Market Cap
- HQH 890.9M
- AKBA 729.1M
- IPO Year
- HQH N/A
- AKBA 2014
- Fundamental
- Price
- HQH $19.69
- AKBA $2.21
- Analyst Decision
- HQH
- AKBA Strong Buy
- Analyst Count
- HQH 0
- AKBA 6
- Target Price
- HQH N/A
- AKBA $6.25
- AVG Volume (30 Days)
- HQH 183.8K
- AKBA 4.5M
- Earning Date
- HQH 01-01-0001
- AKBA 11-10-2025
- Dividend Yield
- HQH 11.56%
- AKBA N/A
- EPS Growth
- HQH N/A
- AKBA N/A
- EPS
- HQH 1.09
- AKBA N/A
- Revenue
- HQH N/A
- AKBA $203,733,000.00
- Revenue This Year
- HQH N/A
- AKBA $43.91
- Revenue Next Year
- HQH N/A
- AKBA $32.09
- P/E Ratio
- HQH $15.24
- AKBA N/A
- Revenue Growth
- HQH N/A
- AKBA 16.75
- 52 Week Low
- HQH $14.31
- AKBA $1.52
- 52 Week High
- HQH $17.94
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- HQH 70.70
- AKBA 32.27
- Support Level
- HQH $19.22
- AKBA $2.07
- Resistance Level
- HQH $19.63
- AKBA $3.19
- Average True Range (ATR)
- HQH 0.31
- AKBA 0.17
- MACD
- HQH -0.01
- AKBA -0.09
- Stochastic Oscillator
- HQH 100.00
- AKBA 12.95
About HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.